Isolated left ventricular assist as bridge to cardiac transplantation

Area of Science:

• Cardiology
• Biomedical Engineering
• Surgical Technology

Background:

• Refractory cardiogenic shock necessitates advanced mechanical circulatory support.
• Left ventricular assist devices (LVADs) offer a potential solution for end-stage heart failure.
• The Novacor implantable LVAD was evaluated for its role as a bridge to transplantation.

Purpose of the Study:

• To assess the safety and efficacy of the Novacor implantable left ventricular assist device (LVAD).
• To evaluate the Novacor LVAD's performance as a bridge to cardiac transplantation in patients with refractory cardiogenic shock.

Main Methods:

• Implantation of the Novacor LVAD in six patients with refractory cardiogenic shock.
• Monitoring of device performance, patient survival, and outcomes post-transplantation.
• Analysis of cardiac index, embolic events, and hemolysis during LVAD support.

Main Results:

• The Novacor LVAD was successfully implanted in six patients.
• Four out of six patients (67%) were successfully bridged to cardiac transplantation.
• The device functioned without mechanical or electrical failure in all cases.
• No embolic events occurred; minimal red cell hemolysis was observed.
• Assist duration ranged from 2 to 16 days, with cardiac index between 2.4-3.4 L/min/m2.

Conclusions:

• The Novacor implantable LVAD is a safe and effective option for bridging patients with refractory cardiogenic shock to cardiac transplantation.
• The device's reliability and positive patient outcomes support its use in select cardiac surgery cases.